Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  Cosimelli, Maurizio ^a   Mancini, Raffaello ^a   Carpanese, Livio ^a   Sciuto, Rosa ^a   Pizzi, Giuseppe ^a   Pattaro, Giada ^a   Maini, Carlo Ludovico ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

90Y; colorectal cancer; liver; metastases; radioembolisation; selective internal radiotherapy; SIRT; yttrium 90 resin microspheres

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MICROSPHERE; OXALIPLATIN; YTTRIUM 90;

ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER STAGING; CHEMORADIOTHERAPY; COLORECTAL CANCER; DRUG DOSE ESCALATION; GASTRITIS; HEPATITIS; HUMAN; LIVER METASTASIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SELECTIVE INTERNAL RADIATION THERAPY; STOMACH ULCER; TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS;

EID: 84858964969     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.647811     Document Type: Article

References (38)

1. Wiering B, Oyen WJ, Adang EM, et al. Long-term global quality of life in patients treated for colorectal liver metastases. Br J Surg 2011;98:565-71
2. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011;22(9):2042-48
3. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010;28:493-508
4. de Haas RJ, Wicherts DA, Andreani P, et al. Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg 2011;253:1069-79
5. Haddad AJ, Hani MB, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol 2011;(Article ID 285840): published online June 2011; doi:10.1155/2011/285840
6. Swan PJ, Welsh FK, Chandrakumaran K, Rees M. Long-term survival following delayed presentation and resection of colorectal liver metastases. Br J Surg 2011;98:1309-17
7. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-80 (Pubitemid 350035315)
8. Neo EL, Beeke C, Price T, et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J Surg 2011;81:352-7
9. 90Y microspheres in the tumour peripheral vasculature.
10. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90) Y microspheres in man: review of four explanted whole livers Int J Radiat Oncol Biol Phys. 2004;60(5):1552-63 (Pubitemid 39601873)
11. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009;20:1121-30
12. Cosimelli M, Golfieri R, Cagol PP, et al. Italian Society of Locoregional Therapies in Oncology (SITILO). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010;103:324-31 This paper describes the first prospective Phase II analysis of radioembolisation as salvage therapy for chemotherapy refractory mCRC.
13. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010;28:3687-94 This Phase III randomised controlled trial provides evidence of prolonged time to progression and safety for radioembolisation combined with chemotherapy compared to chemotherapy alone as salvage therapy for mCRC.
14. Seidensticker M, Denecke T, Kraus P, et al. Match-pair comparison of radioembolisation plus best supportive care versus best support care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Interv Radiol 2011; published online 29 July 2011; doi 10.1007/s00270-011-0234-7 This matched-pair analysis provides evidence of prolonged overall survival following radioembolisation as salvage therapy for chemotherapy refractory mCRC compared to best supportive care in a contemporary setting.
15. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-micropshere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006;65:412-25
16. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008;19:1187-95
17. van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78-85 This Phase II study provides early evidence of the prolonged overall survival which can be achieved by combining radioembolisation with standard chemotherapy compared with chemotherapy alone. (Pubitemid 39536508)
18. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolisation of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007;25:1099-106 This Phase I/II study describes efficacy and safety of combining FOLFOX and radioembolisation. (Pubitemid 46596762)
19. Kosmider S, Tan TH, Yip D, et al. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 2011;22:780-6
20. van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of 5-fluourouracil-refractory patients with liver metastases from colorectal cancer using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009;27:4089-95 This Phase I/II study describes efficacy and safety of combining irinotecan and radioembolisation.
21. Nace GW, Steel JL, Amesur N, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol2011;published online 2011; doi: 10.1155/2011/571261.
22. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
23. Hurwitz H, Fehrenbacher L, Hainsworth J, et al. Bevacizumab in combination with Fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-8
24. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
25. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
26. Maughan T, Adams R, Smith C, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14
27. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
28. van Iersel LBJ, Koopman M, van de Velde CJH, et al. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol 2010;21:1662-7
29. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet 2010;1:38-47
30. Van Cutsem E, Bokemeyer C, Heeger S, et al. Outcomes according to metastatic site in patients with KRAS wt tumors: analysis from the CRYSTAL and OPUS studies [abstract 472]. ASCO GI Cancers Symposium 2011
31. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-18 (Pubitemid 28510874)
32. Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational phase III trial (EFC10262-VELOUR). Ann Oncol 2011;22(5): 1-9
33. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44 (Pubitemid 46733080)
34. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45 (Pubitemid 38944402)
35. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
36. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
37. Wasan H, Kennedy A, Coldwell D, et al. Integrating Radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases. Am J Clin Oncol 2011;published online January 26 2011; doi: 10.1097/COC.0b013e3182005747
38. 90Y microspheres.